| Nov 15 |
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
|
| Nov 13 |
Instil Bio files for $200M mixed securities shelf
|
| Nov 13 |
Instil Bio GAAP EPS of -$3.54
|
| Nov 13 |
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Sep 25 |
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
|
| Sep 17 |
Here's Why Everyone's Talking About Summit Therapeutics
|
| Sep 16 |
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
|
| Sep 16 |
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
|
| Sep 16 |
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
|
| Sep 15 |
Wall Street Breakfast: The Week Ahead
|
